Tenaya Therapeutics, Inc.: directors' dealings · United States · SEC (Form 4)

About Tenaya Therapeutics, Inc.

Tenaya Therapeutics, Inc. is a U.S.-listed biotechnology company trading on the NASDAQ under the ticker TNYA. Headquartered in South San Francisco, California, it operates within one of the most important biotech clusters in the United States. Tenaya is focused on cardiac precision medicine, with a strategy centered on discovering and developing potentially curative therapies that address the underlying drivers of heart disease rather than simply managing symptoms. The company was founded by cardiovascular scientists associated with the Gladstone Institutes and the University of Texas Southwestern Medical Center. From the outset, Tenaya has pursued an integrated platform spanning three interrelated pillars: gene therapy, cellular regeneration, and precision medicine. That platform approach is important from an investor perspective because it gives the company both a near-term clinical asset base and a longer-dated technology franchise. It also reflects a vertically integrated model, including target identification, AAV-based vector design, and in-house manufacturing capabilities, which can be strategically valuable in gene therapy. Tenaya’s most advanced programs are TN-201 and TN-401. TN-201 is a gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM), while TN-401 targets PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC). The pipeline also includes TN-301, a highly selective HDAC6 inhibitor being developed initially for heart failure with preserved ejection fraction (HFpEF). This mix of programs shows a dual focus: rare inherited cardiomyopathies, where clear genetic targets can support a more precise therapeutic hypothesis, and broader heart failure indications with substantial unmet medical need. In competitive terms, Tenaya is operating in a highly specialized segment of biotech where differentiation depends on clinical proof of concept, durability of benefit, safety, manufacturability, and regulatory execution. The company is competing against other gene therapy and precision-cardiology developers, but its positioning is distinct because it is focused specifically on genetic drivers of cardiomyopathy and heart failure. As a clinical-stage company, however, it remains highly dependent on trial outcomes, FDA interactions, and financing access, which are material risks for equity investors. Recent milestones have been important. In 2025 and early 2026, Tenaya reported encouraging interim clinical and preclinical data for TN-201 and TN-401, and it announced the rapid resolution and lifting of a clinical hold on TN-201, which was a meaningful de-risking event for that program. In January 2026, the company said it had raised $60 million in late 2025, extending its runway into mid-2027. For French-speaking investors, the key takeaway is that Tenaya is a high-risk, high-upside NASDAQ biotechnology story in the United States, with a differentiated scientific thesis but still substantial execution, regulatory, and funding risk.